Vancomycin- A Comprehensive Review

Clinical Pharmacology & Microbiology

Mechanism of Action

Vancomycin is a tricyclic glycopeptide that inhibits bacterial cell wall synthesis by binding with high affinity to the D-alanyl-D-alanine terminus of cell wall precursor units. This binding sterically hinders the transglycosylase and transpeptidase enzymes, preventing peptidoglycan polymerization and cross-linking.

Spectrum of Activity

• Gram-Positive Aerobes: Staphylococcus aureus (including MRSA), Coagulase-negative Staphylococci (CoNS), Streptococcus spp. (including MDR S. pneumoniae), Enterococcus spp. (bacteriostatic only), Corynebacterium jeikeium.
• Gram-Positive Anaerobes: Clostridioides difficile (oral only), Propionibacterium spp., Peptostreptococcus.
• Gaps: No activity against Gram-negatives or Mycobacteria. Intrinsic resistance in Leuconostoc, Pediococcus, and Erysipelothrix (useful identification clue: if it looks like Staph/Strep but is Vanc-resistant, think of these).

Advanced PK/PD & Monitoring (The 2020 Guideline Shift)

The 2020 ASHP/IDSA/PIDS/SIDP consensus guidelines recommend moving away from trough-only monitoring to AUC/MIC monitoring.

The Target: AUC/MIC

• Efficacy Target: AUC₂₄/MIC ≥ 400 (assuming broth microdilution MIC of 1 mg/L).
• Toxicity Threshold: AUC₂₄> 600 mg·h/L is associated with increased nephrotoxicity.
• Why the shift? Trough monitoring is a poor surrogate for AUC. Troughs of 15–20 mg/L often result in AUCs >600, unnecessarily increasing nephrotoxicity risk without improving efficacy.

Dosing Strategies

1. Standard Adult Dosing (Systemic Infection)

• Loading Dose: 20–35 mg/kg (Max 3,000 mg). Base on Actual Body Weight (ABW).
  • Indication: Critically ill, sepsis, osteomyelitis, meningitis.
• Maintenance: 15–20 mg/kg q8–12h initially. Adjust to achieve AUC 400–600.
  • Max single dose: Generally capped at 2g (some allow 2.5g) to prevent infusion reactions. Infusion time: 1 hour per 1000 mg.

2. Obesity (BMI > 30 kg/m²)

• Volume of Distribution (Vd): Vancomycin distributes into adipose tissue, but less than lean tissue. Vd approximates 0.7 L/kg.
• Dosing: Use Actual Body Weight for loading.
• Maintenance: Empiric capping at 4,500 mg/day is common before levels are drawn.
• Consultant Pearl: Obese patients often have hyperfiltration (high glomerular filtration). They may require q8h dosing despite “normal” creatinine.

3. Renal Impairment & Dialysis

4. Augmented Renal Clearance (ARC)

• Population: Trauma, burns, cystic fibrosis, young neuro-critical care patients (CrCl > 130 mL/min).
• Challenge: Standard doses result in subtherapeutic troughs (<10 mg/L).
• Strategy: Aggressive regimens required. Often 30 mg/kg/day divided q6h or q8h. Consider continuous infusion (CI) if targets are impossible to hit with intermittent dosing.

5. CNS Infections (Meningitis/Ventriculitis)

• Systemic Penetration: Poor. ~1% with non-inflamed meninges; 20-40% with inflamed meninges.
• Systemic Target: Target Trough 15–20 mg/L (AUC/MIC targets less validated here, stick to high exposure).
• Intraventricular/Intrathecal: Used when systemic therapy fails.
  • Dose: 5–20 mg daily (clamped EVD for 1 hour).
  • Target: CSF Trough 10–20 mg/L.

Adverse Effects & Interactions

1. Vancomycin Infusion Reaction (“Red Man Syndrome”)

• Mechanism: Direct mast cell degranulation (Non-IgE mediated). Histamine release causes flushing, pruritus, hypotension.
• Management: Stop infusion, administer diphenhydramine. Restart at 50% of the original rate once symptoms resolve.
• Prevention: Infuse max 1g/hour (or 10 mg/min). Pre-medicate with antihistamines if recurrent.

2. Nephrotoxicity

• Risk Factors: Troughs > 20 mg/L, AUC > 600, duration > 7 days, concomitant nephrotoxins.
• The “Pip/Tazo” Synergy: Concomitant use of Piperacillin-Tazobactam + Vancomycin significantly increases AKI risk (OR ~3.0) compared to Vancomycin + Cefepime or Meropenem.
  • Action: In patients with tenuous renal function, prefer Cefepime or Meropenem as the Gram-negative partner.

3. Ototoxicity

• Rare. Usually associated with very high levels (>80 mg/L) or concomitant aminoglycosides/loop diuretics. Can be permanent.

Consultant Pearls

• Surgical Prophylaxis: Use 15 mg/kg. Must be started within 120 minutes of incision (due to long infusion time). Re-dose only if surgery > 6-8 hours or massive blood loss (>1500mL).
• “Steady State” Myth: In unstable renal function (AKI), do not wait for steady state (3-4 doses) to check a level. Check a “random” level 12-24 hours after the first dose to ensure clearance is occurring. If the level is still 25 mg/L, you need to hold; if it’s 5 mg/L, you are underdosing.
• Oral Vancomycin: Has 0% oral bioavailability. Used exclusively for C. difficile.
  • First occurrence: 125 mg PO QID x 10 days.
  • Recurrence: Taper/Pulse regimens (e.g., QID x 14d -> BID x 7d -> Daily x 7d -> q2-3 days x 2-8 weeks).
• When to Switch (MRSA Bacteremia): If bacteremia persists > 7 days despite adequate AUC/troughs, suspect biofilm seeding. Switch to Daptomycin (6-10 mg/kg) or Ceftaroline (salvage).
• Newer Lipoglycopeptides:
  • Dalbavancin/Oritavancin: Extremely long half-lives (>200 hours). Single or two-dose regimens. Excellent for facilitating early discharge in SSTI or osteomyelitis (off-label).

Summary: The “Why” Then vs. Now

References And Further Reading

1. Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm. 2020;77(11):835-864.
2. Stewart JJ, Jorgensen SCJ, Dresser L, et al. A Canadian perspective on the revised 2020 ASHP–IDSA–PIDS–SIDP guidelines for vancomycin AUC-based therapeutic drug monitoring for serious MRSA infections. JAC-Antimicrobial Resistance. 2021;3(1):dlaa135.
3. Wysocki M, Delatour F, Faurisson F, et al. Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother. 2001;45(9):2460-2467.
4. Lodise TP, Patel N, Lomaestro BM, et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009;49(4):507-514.
5. Aljefri DM, Avedissian SN, Rhodes NJ, et al. Vancomycin Area Under the Curve and Acute Kidney Injury: A Meta-analysis. Clin Infect Dis. 2019;69(11):1881-1887.
6. Burgess LD, Drew RH. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. Pharmacotherapy. 2014;34(7):670-676.
7. Pai MP, Neely M, Rodvold KA, Lodise TP. Innovative approaches to optimizing the delivery of vancomycin in individual patients. Adv Drug Deliv Rev. 2014;77:50-57.
8. Heil EL, Claeys KC, Mynatt RP, et al. Making the change to area under the curve-based vancomycin dosing. Am J Health-Syst Pharm. 2018;75(24):1986-1995.

Dr Kunal Varma Bheecarry

Dr. Kunal Varma Bheecarry, MD is a GMC registered substantive Consultant Physician in the UK, specializing in Internal Medicine. With more than 15 years of experience on the clinical frontlines in both General Internal Medicine and Acute Medicine, he is passionate about translating complex medical topics, common problems and clinical guidelines into clear, actionable knowledge for healthcare professionals and patients alike. Every article is written and rigorously reviewed by him and other registered medical professionals to ensure clinical accuracy, guideline compliance, evidence-based reliability, authoritativeness and trustworthiness.

Disclaimer: All content is purely educational and does not constitute personal medical advice. It is not a substitute for professional clinical advice and readers must consult their own primary team. All views and interpretations are mine and not related to the work place.